Table 1.

Trials with endocrine therapy resistance (without PI3K/Akt/mTOR or CDK4/6/Rb pathways inhibition).

Reference	Target/pathway	Results	PFS
Paul et al., 2013	Dasatinib	Phase IIR First line	Let: 9.9 months
	(Inhibitor of SRC)	n = 120	Let + dasa: 20.1 months
Yardley et al., 2013	Entinostat	Phase IIR Second line	Exe 2.3 months
	(Inhibitor of HDAC)	n = 130	Exe + enti: 4.3 months
Trifonidiseur et al., 2016	Gefinitib	Phase IIR First line	Ana + gef: 35% (at 1 year)
	Anti HER1	n = 71	Ana: 32% (at 1 year)
Robertson et al., 2013	Ganitumab	Phase IIR	Ful ou exe + gan: 3.9 months
	Anti IGF1	n = 156	Ful ou exe: 5.7 months
Kaufmann et al., 2009	HER 2	Phase III, First line	Ana + trast: 4.8 months versus
	Trastuzumab	n = 207	Ana 2.4 months
Jonhston et al., 2009	HER2	Phase III, First line	Lapa + let: 8.3 months
	Lapatinib	n = 1286	Let: 3 months

Dasa, dasatinib; let, letrozole; exe, exemestane; enti, entinostat; gan, ganitumab; gef, gefitinib; ana, anastrozole; ful, fulvestrant; trast, trastuzumab; lapa, lapatinib; SRC, sarcoma; HDAC, histone deacetylase inhibitors; PFS, progression-free survival.